Article Text

Download PDFPDF

Comorbidities and rheumatological diseases at the time of COVID-19. Response to: ‘Rheumatic diseases in intensive care unit patients with COVID-19’ by Moiseev et al
Free
  1. Sara Monti,
  2. Carlomaurizio Montecucco
  1. Rheumatology, Fondazione IRCCS Policlinico San Matteo, Pavia, Lombardia, Italy
  1. Correspondence to Dr Sara Monti, Rheumatology, Fondazione IRCCS Policlinico San Matteo, 27100 Pavia, Italy; sara.saramonti{at}gmail.com

Statistics from Altmetric.com

We thank Dr Moiseev et al 1 for their comment on our previous paper on the clinical course of severe acute respiratory syndrome Coronavirus-2 (SARS-CoV-2) disease 2019 (COVID-19) in patients treated with biologic and targeted synthetic disease-modifying anti-rheumatic drugs.2 The authors assessed the outcome of patients with inflammatory rheumatic diseases among patients admitted to the intensive care unit (ICU) and reported findings in line with our cohort of outpatients.2 Admission to the ICU due to COVID-19 in patients with rheumatic diseases did not exceed those expected in the general population. Nevertheless, the mortality of these patients was 50%. Interestingly, Moiseev et al 1 reported that the majority of rheumatologic patients admitted to the ICU had concurrent conditions including hypertension, previous cardiovascular events or diabetes mellitus. These same comorbidities had been previously identified as risk factors associated with worse outcome also in the general population affected by COVID-19.3 This comment confirms the cautious impression that patients with rheumatologic diseases might not have a worse prognosis during COVID-19 and that underlying concomitant cardiovascular comorbidities might influence the severity of the infection. Nevertheless, the mortality rate of patients admitted to the ICU is still relevant, and patients with a significant comorbidity burden might be particularly at risk. Comorbidities are frequent in patients with rheumatologic diseases, even at a younger age compared with control populations,4 5 and these might expose our patients to an excessive risk in case of severe SARS-CoV-2 infection.

References

View Abstract

Footnotes

  • Handling editor Josef S Smolen

  • Contributors SM and CM wrote and revised the manuscript.

  • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

  • Competing interests None declared.

  • Patient and public involvement Patients and/or the public were not involved in the design, or conduct, or reporting, or dissemination plans of this research.

  • Patient consent for publication Not required.

  • Provenance and peer review Commissioned; internally peer reviewed.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Linked Articles

  • Correspondence
    Sergey Moiseev Sergey Avdeev Michail Brovko Andrey Yavorovskiy Pavel I Novikov Karina Umbetova Larisa Akulkina Natal'ya Tsareva Victor Fomin